Why Axsome Therapeutics Stock Rocketed Higher to End 2025 [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
Auvelity sales soared 69% in Q3. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ: AXSM) shares soared to close out the year. The company released two items of news today. Investors see one in particular as a meaningful catalyst for the biopharmaceutical company that specializes in developing therapies for the management of depression and other neurological conditions. Axsome shares rocketed more than 20% higher, and remained up by 19.4% as of 12:10 p.m. ET. Axsome announced today that the U.S. Food and Drug Administration (FDA) granted priority review designation for its AXS-05 drug for the treatment of Alzheimer's disease agitation. Axsome already has approval for the medicine to treat adults with major depressive disorder (MDD). Branded as Auvelity, sales of the drug grew 69% year-over-year in Q3 and accounted for 80% of Axsome's revenue for the quarter. The FDA has set a target action date of April 30, 2026, giving investors a shortened ti
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of FibromyalgiaGlobeNewswire
- Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) was given a new $209.00 price target on by analysts at Robert W. Baird.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- MoneyShow's Best Investment Ideas For 2026: Part 2 [Seeking Alpha]Seeking Alpha
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- AXSM's page on the SEC website